## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

Claims 1-9 (Cancelled)

10. (Currently Amended) A method for treating in a human being diffuse macular edema in diabetic maculopathy in a mammal-comprising administering to the subject an effective amount of a compound represented by the following general formula:

wherein X represents a halogen or a hydrogen atom, and R<sup>1</sup> and R<sup>2</sup> concurrently or differently represent a hydrogen atom or a C1 to C6 alkyl group.

- 11. (Currently Amended) The method for treating in a human being diffuse macular edema in diabetic maculopathy according to claim 10, wherein the compound is administered in the form of an oral agent.
- 12. (Currently Amended) The method for treating in a human being diffuse macular edema in diabetic maculopathy according to claim 10, wherein the compound is (2S, 4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide.

## 13. (Cancelled)

14. (Previously Presented) A method for improving visual acuity and inhibiting a deterioration of visual acuity in diabetic maculopathy comprising the method according to claim 10.

Claims 15-17 (Cancelled)